Intelligent Bio Solutions Reports 98.2% Accuracy In Codeine Study, Accelerates FDA 510(k) Submission To September 2026
Intelligent Bio Solutions Inc. (NASDAQ:INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the results of its
A medical company found their test correctly identifies codeine 98.2% of the time, which is really accurate. When a company shows strong test results and moves faster toward government approval, it suggests they're making real progress—something to watch as the story develops.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.